Andrew Danziger

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Medicine · Health Sciences

8h-index535citations14works6.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Migraine and Headache Studies(5), Neuropeptides and Animal Physiology(4), Neuroscience and Neuropharmacology Research(2), Receptor Mechanisms and Signaling(2), Nicotinic Acetylcholine Receptors Study(2)

Publications14 total

MK-7602: a potent multi-stage dual-targeting antimalarial
EBioMedicine·2025· 1 citedOpen Access
Elucidating the immunogenic mechanisms of Lipid Nanoparticle (LNP) adjuvants 2411
The Journal of Immunology·2025Open Access
Pharmacologic characterization of atogepant: A potent and selective calcitonin gene–related peptide receptor antagonist
Cephalalgia·2024· 18 citedOpen Access
Evaluation of luciferase and prefusion-stabilized F protein from respiratory syncytial virus mRNA/LNPs in pre-clinical models using jet delivery compared to needle and syringe
Vaccine X·2023· 3 citedOpen Access
Na <sub>v</sub> 1.7 target modulation and efficacy can be measured in nonhuman primate assays
Science Translational Medicine·2021· 20 cited
Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene‒Related Peptide Receptor
Journal of Pharmacology and Experimental Therapeutics·2020· 70 citedOpen Access
Transforaminal lumbar puncture for intrathecal access: Case series with literature review and comparison to other techniques
Journal of Clinical Neuroscience·2020· 10 cited
Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene-Related Peptide Receptor (P4.10-021)
Neurology·2019· 3 cited
Novel oxazolidinone calcitonin gene-related peptide (CGRP) receptor antagonists for the acute treatment of migraine
Bioorganic & Medicinal Chemistry Letters·2015· 25 cited
Pharmacological Properties of MK-3207, a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor Antagonist
Journal of Pharmacology and Experimental Therapeutics·2010· 88 cited
Selective activation of the M <sub>1</sub> muscarinic acetylcholine receptor achieved by allosteric potentiation
Proceedings of the National Academy of Sciences·2009· 282 citedOpen Access
Attenuation of edema and infarct volume following focal cerebral ischemia by early but not delayed administration of a novel small molecule KDR kinase inhibitor
Neuroscience Research·2008· 12 cited
P4‐332: <i>In vivo</i> pharmacodynamic effects of BQCA, a novel selective allosteric M1 receptor modulator
Alzheimer s & Dementia·2008· 3 cited
Therapeutic renal infarction.
PubMed·1978

Frequent Co-authors

Christopher P. Regan(7), Christopher Salvatore(5), Eric L. Moore(5), Rebecca B. White(5), Christopher S. Burgey(5), Chi‐Chung Li(4), Ian M. Bell(4), Mark E. Fraley(4), Pradeep Banerjee(3), Marion Wittmann(2), Guangping Xu(2), Michelle Pearson(2), Susan L. Garson(2), Scott M. Doran(2), Cyrille Sur(2), Guy R. Seabrook(2), William J. Ray(2), Maria S. Michener(2), Joseph J. Lynch(2), Harold G. Selnick(2)